Cargando…

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study

This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n = 231). Mean liver iron concentrations (LIC) decreased significantly from 21.1 ± 8.2 to 14.2 ± 12.1 mg Fe/g dry weight (dw)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taher, Ali, Elalfy, Mohsen S, Al Zir, Kusai, Daar, Shahina, Al Jefri, Abdullah, Habr, Dany, Kriemler-Krahn, Ulrike, Roubert, Bernard, El-Beshlawy, Amal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2011
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229710/ https://www.ncbi.nlm.nih.gov/pubmed/21668501 http://dx.doi.org/10.1111/j.1600-0609.2011.01661.x

Ejemplares similares

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2009)

Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia
por: Taher, Ali, et al.
Publicado: (2011)

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Noninvasive Measurement of Liver Iron Concentration
por: St Pierre, Tim G, et al.
Publicado: (2014)

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
por: Daar, Shahina, et al.
Publicado: (2009)

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy
por: Porter, J. B., et al.
Publicado: (2012)

Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
por: Pathare, Anil, et al.
Publicado: (2009)

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
por: Porter, John B, et al.
Publicado: (2011)

Worldwide survey of T2* cardiovascular magnetic resonance in Thalassaemia
por: Carpenter, John-Paul, et al.
Publicado: (2011)

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®)
por: Vini, Dimitra, et al.
Publicado: (2011)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Thalassaemia Intermedia: an Update
por: Taher, Ali T., et al.
Publicado: (2009)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
por: Taher, Ali T, et al.
Publicado: (2013)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
por: Taher, Ali T., et al.
Publicado: (2013)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis
por: Phatak, Pradyumna, et al.
Publicado: (2010)

α-thalassaemia
por: Harteveld, Cornelis L, et al.
Publicado: (2010)

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
por: Porter, John, et al.
Publicado: (2012)

When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia
por: Taher, A T, et al.
Publicado: (2015)

An ICET- A survey on hypoparathyroidism in patients with thalassaemia major and intermedia: a preliminary report
por: De Sanctis, Vincenzo, et al.
Publicado: (2017)

Perforated duodenal ulcer: A rare complication of deferasirox in children
por: Yadav, Sunil Kumar, et al.
Publicado: (2013)

Screening for beta thalassaemia
por: Petrou, Mary
Publicado: (2010)

2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia
por: Farmakis, Dimitrios, et al.
Publicado: (2022)

Deferasirox: Duodenal perforation: case report
Publicado: (2021)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

PB2540: HEPATIC SAFETY PROFILE OF DEFERASIROX IN CHILDREN WITH BETA THALASSEMIA MAJOR IN OMAN
por: Almadhani, Shaimaa, et al.
Publicado: (2023)

Thalassaemia and Aberrations of Growth and Puberty
por: Kyriakou, Andreas, et al.
Publicado: (2009)

THALASSAEMIA IS A TROPICAL DISEASE
por: Kotila, T.R.
Publicado: (2012)

Improved efficiency and patient safety through bespoke electronic thalassaemia care module
por: Naveed, Mohamed, et al.
Publicado: (2019)

Observational study on the current status of thalassaemia in Malaysia: a report from the Malaysian Thalassaemia Registry
por: Mohd Ibrahim, Hishamshah, et al.
Publicado: (2020)

The parental perspective of thalassaemia in Bangladesh: lack of knowledge, regret, and barriers
por: Hossain, Mohammad Sorowar, et al.
Publicado: (2021)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Deferasirox – a rarer cause of Fanconi syndrome
por: Khan, Iman, et al.
Publicado: (2019)

Synthesis and Study of Multifunctional Cyclodextrin–Deferasirox Hybrids
por: Gascon, Jose Miguel, et al.
Publicado: (2019)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
por: Galeotti, Laura, et al.
Publicado: (2021)

Evaluation of Serum Leptin Levels and Growth in Patients with β-Thalassaemia Major
por: Al-Naama, Lamia Mustafa, et al.
Publicado: (2016)

Longitudinal Study on Liver Functions in Patients with Thalassemia Major before and after Deferasirox (DFX) Therapy
por: Soliman, Ashraf, et al.
Publicado: (2014)

Molecular Characterization of α- and β-Thalassaemia among Malay Patients
por: Mohd Yatim, Nur Fatihah, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tmp81nif0hj2p5p2vq6aqondim